Given the limited advancements in systemic treatment of STS, including targeted therapies and immune checkpoint inhibitors, incorporating the activation STING pathway into standard chemotherapy regimens may offer a promising strategy to improve clinical outcomes for this challenging disease. The gene discussed is STING1; the disease is telomere syndrome.